NDAORAL-21TABLET
Approved
May 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO-NOVUM 1/50 21 is an oral contraceptive tablet containing mestranol and norethindrone, approved in 1962. It prevents pregnancy through combined hormonal suppression of ovulation and is taken as a 21-day cyclical regimen.
LOE Approaching
Product is in late lifecycle decline with moderate competitive pressure (30%), suggesting team focus is on managed extinction rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ORTHO-NOVUM 1/50 21 offers limited growth trajectory and career advancement, as the product is approaching loss of exclusivity with minimal linked job openings. This role is suited for professionals managing product discontinuation, generic transition, or mature portfolio stewardship rather than career acceleration.
Brand Manager (Legacy Products)Regulatory Affairs Specialist
Worked on ORTHO-NOVUM 1/50 21 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.